Acute nonlymphoblastic leukemia in children treated for acute lymphoblastic leukemia with an intensive regimen including teniposide
Some cases of conversion from acute lymphoblastic leukemia (ALL) to acute nonlymphoblastic leukemia (ANLL) at relapse have been reported recently. We report three cases initially diagnosed as having ALL and showing morphological, cytochemical, and immunophenotypic features of ANLL at relapse (lineag...
Gespeichert in:
| Veröffentlicht in: | Medical and pediatric oncology 1992, Vol.20 (1), p.48-52 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 52 |
|---|---|
| container_issue | 1 |
| container_start_page | 48 |
| container_title | Medical and pediatric oncology |
| container_volume | 20 |
| creator | Verdeguer, Amparo Ruiz, Jose Gabriel Ferris, Josep Esquembre, Carlos Tasso, Maria Jesus Fernandez, Jose Maria Prieto, Felix Castel, Victoria |
| description | Some cases of conversion from acute lymphoblastic leukemia (ALL) to acute nonlymphoblastic leukemia (ANLL) at relapse have been reported recently. We report three cases initially diagnosed as having ALL and showing morphological, cytochemical, and immunophenotypic features of ANLL at relapse (lineage switch). Conversion was observed among 14 patients who developed bone marrow relapse while undergoing intensive treatment with our ALL protocol, which includes teniposide, and that had been administered to 62 patients. The three cases converted at first relapse, with a mean time of 20 months (13–29 months). Clinical and immunologic characteristics of T‐cell leukemia were present in one patient. Changes documented in cytogenetic studies are discussed. The underlying mechanisms for the lineage switch remain unclear as does its relation with mixed lineage leukemias, but we believe that drugs employed in our therapy protocol could have had an influence on this conversion. |
| doi_str_mv | 10.1002/mpo.2950200110 |
| format | Article |
| fullrecord | <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_mpo_2950200110</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_513W89SX_V</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4070-48fe15ed503a86f96dc8560f5034aed6bb766ae1333798b18abd74a386f8fac83</originalsourceid><addsrcrecordid>eNqFkMtOwzAURC0EgvLYskPyD6TYcRLbywpBQQKKxHNnOfENNeQlO6F0zY-TEkTFArG6mjtzZjEIHVIypoSEx2VTj0MZk5AQSskGGlEik0BS-rSJRoRIEdCYhTto1_sX0mvJxTbapjzkIaUj9DHJuhZwVVfFsmzmdVpo39oMF9C9Qmk1thXO5rYwDircOtAtGJzXDusv7g9oYds51lUPt1B5-wbYwbMtYfXJis7Y6hn3jm1qbw3so61cFx4Ovu8euj87vTs5Dy5n04uTyWWQRYSTIBI50BhMTJgWSS4Tk4k4IXmvIw0mSVOeJBooY4xLkVKhU8MjzfqsyHUm2B4aD72Zq713kKvG2VK7paJErcZU_ZhqPWYPHA1A06UlmHV8WK_35eAvbAHLf9rU1c3sV3cwsNa38P7DaveqEs54rB6vpyqm7FHI2yf1wD4B_eaTpA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Acute nonlymphoblastic leukemia in children treated for acute lymphoblastic leukemia with an intensive regimen including teniposide</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Verdeguer, Amparo ; Ruiz, Jose Gabriel ; Ferris, Josep ; Esquembre, Carlos ; Tasso, Maria Jesus ; Fernandez, Jose Maria ; Prieto, Felix ; Castel, Victoria</creator><creatorcontrib>Verdeguer, Amparo ; Ruiz, Jose Gabriel ; Ferris, Josep ; Esquembre, Carlos ; Tasso, Maria Jesus ; Fernandez, Jose Maria ; Prieto, Felix ; Castel, Victoria</creatorcontrib><description>Some cases of conversion from acute lymphoblastic leukemia (ALL) to acute nonlymphoblastic leukemia (ANLL) at relapse have been reported recently. We report three cases initially diagnosed as having ALL and showing morphological, cytochemical, and immunophenotypic features of ANLL at relapse (lineage switch). Conversion was observed among 14 patients who developed bone marrow relapse while undergoing intensive treatment with our ALL protocol, which includes teniposide, and that had been administered to 62 patients. The three cases converted at first relapse, with a mean time of 20 months (13–29 months). Clinical and immunologic characteristics of T‐cell leukemia were present in one patient. Changes documented in cytogenetic studies are discussed. The underlying mechanisms for the lineage switch remain unclear as does its relation with mixed lineage leukemias, but we believe that drugs employed in our therapy protocol could have had an influence on this conversion.</description><identifier>ISSN: 0098-1532</identifier><identifier>EISSN: 1096-911X</identifier><identifier>DOI: 10.1002/mpo.2950200110</identifier><identifier>PMID: 1727211</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>acute lymphoblastic leukemia ; acute mixed lineage leukemia ; Child, Preschool ; Female ; Humans ; Immunophenotyping ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - etiology ; Male ; Neoplasms, Second Primary - chemically induced ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; secondary acute nonlymphoblastic leukemia ; switch lineage ; Teniposide - adverse effects ; Teniposide - therapeutic use</subject><ispartof>Medical and pediatric oncology, 1992, Vol.20 (1), p.48-52</ispartof><rights>Copyright © 1992 Wiley‐Liss, Inc., A Wiley Company</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4070-48fe15ed503a86f96dc8560f5034aed6bb766ae1333798b18abd74a386f8fac83</citedby><cites>FETCH-LOGICAL-c4070-48fe15ed503a86f96dc8560f5034aed6bb766ae1333798b18abd74a386f8fac83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmpo.2950200110$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmpo.2950200110$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,4010,27904,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1727211$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Verdeguer, Amparo</creatorcontrib><creatorcontrib>Ruiz, Jose Gabriel</creatorcontrib><creatorcontrib>Ferris, Josep</creatorcontrib><creatorcontrib>Esquembre, Carlos</creatorcontrib><creatorcontrib>Tasso, Maria Jesus</creatorcontrib><creatorcontrib>Fernandez, Jose Maria</creatorcontrib><creatorcontrib>Prieto, Felix</creatorcontrib><creatorcontrib>Castel, Victoria</creatorcontrib><title>Acute nonlymphoblastic leukemia in children treated for acute lymphoblastic leukemia with an intensive regimen including teniposide</title><title>Medical and pediatric oncology</title><addtitle>Med. Pediatr. Oncol</addtitle><description>Some cases of conversion from acute lymphoblastic leukemia (ALL) to acute nonlymphoblastic leukemia (ANLL) at relapse have been reported recently. We report three cases initially diagnosed as having ALL and showing morphological, cytochemical, and immunophenotypic features of ANLL at relapse (lineage switch). Conversion was observed among 14 patients who developed bone marrow relapse while undergoing intensive treatment with our ALL protocol, which includes teniposide, and that had been administered to 62 patients. The three cases converted at first relapse, with a mean time of 20 months (13–29 months). Clinical and immunologic characteristics of T‐cell leukemia were present in one patient. Changes documented in cytogenetic studies are discussed. The underlying mechanisms for the lineage switch remain unclear as does its relation with mixed lineage leukemias, but we believe that drugs employed in our therapy protocol could have had an influence on this conversion.</description><subject>acute lymphoblastic leukemia</subject><subject>acute mixed lineage leukemia</subject><subject>Child, Preschool</subject><subject>Female</subject><subject>Humans</subject><subject>Immunophenotyping</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - etiology</subject><subject>Male</subject><subject>Neoplasms, Second Primary - chemically induced</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>secondary acute nonlymphoblastic leukemia</subject><subject>switch lineage</subject><subject>Teniposide - adverse effects</subject><subject>Teniposide - therapeutic use</subject><issn>0098-1532</issn><issn>1096-911X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOwzAURC0EgvLYskPyD6TYcRLbywpBQQKKxHNnOfENNeQlO6F0zY-TEkTFArG6mjtzZjEIHVIypoSEx2VTj0MZk5AQSskGGlEik0BS-rSJRoRIEdCYhTto1_sX0mvJxTbapjzkIaUj9DHJuhZwVVfFsmzmdVpo39oMF9C9Qmk1thXO5rYwDircOtAtGJzXDusv7g9oYds51lUPt1B5-wbYwbMtYfXJis7Y6hn3jm1qbw3so61cFx4Ovu8euj87vTs5Dy5n04uTyWWQRYSTIBI50BhMTJgWSS4Tk4k4IXmvIw0mSVOeJBooY4xLkVKhU8MjzfqsyHUm2B4aD72Zq713kKvG2VK7paJErcZU_ZhqPWYPHA1A06UlmHV8WK_35eAvbAHLf9rU1c3sV3cwsNa38P7DaveqEs54rB6vpyqm7FHI2yf1wD4B_eaTpA</recordid><startdate>1992</startdate><enddate>1992</enddate><creator>Verdeguer, Amparo</creator><creator>Ruiz, Jose Gabriel</creator><creator>Ferris, Josep</creator><creator>Esquembre, Carlos</creator><creator>Tasso, Maria Jesus</creator><creator>Fernandez, Jose Maria</creator><creator>Prieto, Felix</creator><creator>Castel, Victoria</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1992</creationdate><title>Acute nonlymphoblastic leukemia in children treated for acute lymphoblastic leukemia with an intensive regimen including teniposide</title><author>Verdeguer, Amparo ; Ruiz, Jose Gabriel ; Ferris, Josep ; Esquembre, Carlos ; Tasso, Maria Jesus ; Fernandez, Jose Maria ; Prieto, Felix ; Castel, Victoria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4070-48fe15ed503a86f96dc8560f5034aed6bb766ae1333798b18abd74a386f8fac83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>acute lymphoblastic leukemia</topic><topic>acute mixed lineage leukemia</topic><topic>Child, Preschool</topic><topic>Female</topic><topic>Humans</topic><topic>Immunophenotyping</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - etiology</topic><topic>Male</topic><topic>Neoplasms, Second Primary - chemically induced</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>secondary acute nonlymphoblastic leukemia</topic><topic>switch lineage</topic><topic>Teniposide - adverse effects</topic><topic>Teniposide - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>Verdeguer, Amparo</creatorcontrib><creatorcontrib>Ruiz, Jose Gabriel</creatorcontrib><creatorcontrib>Ferris, Josep</creatorcontrib><creatorcontrib>Esquembre, Carlos</creatorcontrib><creatorcontrib>Tasso, Maria Jesus</creatorcontrib><creatorcontrib>Fernandez, Jose Maria</creatorcontrib><creatorcontrib>Prieto, Felix</creatorcontrib><creatorcontrib>Castel, Victoria</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Medical and pediatric oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Verdeguer, Amparo</au><au>Ruiz, Jose Gabriel</au><au>Ferris, Josep</au><au>Esquembre, Carlos</au><au>Tasso, Maria Jesus</au><au>Fernandez, Jose Maria</au><au>Prieto, Felix</au><au>Castel, Victoria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute nonlymphoblastic leukemia in children treated for acute lymphoblastic leukemia with an intensive regimen including teniposide</atitle><jtitle>Medical and pediatric oncology</jtitle><addtitle>Med. Pediatr. Oncol</addtitle><date>1992</date><risdate>1992</risdate><volume>20</volume><issue>1</issue><spage>48</spage><epage>52</epage><pages>48-52</pages><issn>0098-1532</issn><eissn>1096-911X</eissn><abstract>Some cases of conversion from acute lymphoblastic leukemia (ALL) to acute nonlymphoblastic leukemia (ANLL) at relapse have been reported recently. We report three cases initially diagnosed as having ALL and showing morphological, cytochemical, and immunophenotypic features of ANLL at relapse (lineage switch). Conversion was observed among 14 patients who developed bone marrow relapse while undergoing intensive treatment with our ALL protocol, which includes teniposide, and that had been administered to 62 patients. The three cases converted at first relapse, with a mean time of 20 months (13–29 months). Clinical and immunologic characteristics of T‐cell leukemia were present in one patient. Changes documented in cytogenetic studies are discussed. The underlying mechanisms for the lineage switch remain unclear as does its relation with mixed lineage leukemias, but we believe that drugs employed in our therapy protocol could have had an influence on this conversion.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>1727211</pmid><doi>10.1002/mpo.2950200110</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0098-1532 |
| ispartof | Medical and pediatric oncology, 1992, Vol.20 (1), p.48-52 |
| issn | 0098-1532 1096-911X |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_mpo_2950200110 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | acute lymphoblastic leukemia acute mixed lineage leukemia Child, Preschool Female Humans Immunophenotyping Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - etiology Male Neoplasms, Second Primary - chemically induced Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy secondary acute nonlymphoblastic leukemia switch lineage Teniposide - adverse effects Teniposide - therapeutic use |
| title | Acute nonlymphoblastic leukemia in children treated for acute lymphoblastic leukemia with an intensive regimen including teniposide |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A18%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20nonlymphoblastic%20leukemia%20in%20children%20treated%20for%20acute%20lymphoblastic%20leukemia%20with%20an%20intensive%20regimen%20including%20teniposide&rft.jtitle=Medical%20and%20pediatric%20oncology&rft.au=Verdeguer,%20Amparo&rft.date=1992&rft.volume=20&rft.issue=1&rft.spage=48&rft.epage=52&rft.pages=48-52&rft.issn=0098-1532&rft.eissn=1096-911X&rft_id=info:doi/10.1002/mpo.2950200110&rft_dat=%3Cistex_cross%3Eark_67375_WNG_513W89SX_V%3C/istex_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/1727211&rfr_iscdi=true |